PHARMA
Block deals worth over Rs 8,228 crore this week; TCS, ICICI Bank, Power Grid lead the action
The small-cap segment saw Rs 812 crore worth of block deals this week. Ramco Industries led the small-cap deals with Rs 327 crore, followed by Five-Star Business Finance at Rs 97 crore and Genesys International at Rs 86 crore.
India Inc: Key takeaways from Q2 earnings season for investors
The second quarter of FY25 saw mixed financial results for Nifty 50 companies. While Pharma and Realty thrived, Energy and Infrastructure struggled. Factors like uneven rainfall and inflation impacted sectors like FMCG and Auto. Despite challenges, companies adapted through operational efficiency and strategic initiatives, with optimism for a stronger second half of the fiscal year.
Stock Radar: 100% rally in a year! This pharma company takes support above 50-EMA; time to buy the dip?
Piramal Pharma's stock, after reaching record highs, experienced profit-taking but is showing signs of a bullish comeback. Experts suggest buying the stock, citing its rebound from the 50-day EMA and strong trading volume, with a potential target of Rs 280-286 in the coming weeks.
These 15 mid-cap stocks with ¡®Strong Buy¡¯ & ¡®Buy¡¯ recos can rally over 33%, according to analysts
In the short term, stock prices are impacted by events and the narratives built around them. For the next session or two, they could be impacted by the Maharashtra election exit polls and news flow from the Ukraine-Russia front. In the medium- to long-term, however, stock prices and the absolute value of stocks depend on the fundamentals of the sector ¨C as well as valuations, which are still high despite the latest correction. But, at the same time, fundamentals are improving for several industries. So, analysts are bullish about specific sectors and stocks. If the Nifty and market breadth stay positive in the coming trading sessions, it is likely we will see mid-caps gaining strength. It would also probably signal the end of this phase of correction, which began in October.
As smog engulfs the street, essential pills for a healthy of portfolio: 5 pharma stocks with an upside potential of up to 39%
Here¡¯s a lesson from history: For a long-term investor, buying in a correcting market is mostly an opportunity. The operative part, of course, is ¡°long-term investor¡± ¨C not people who check the value of their portfolio every evening. Also, focus on a sector that is making a comeback. Why? Because when a sector catches the limelight for the first time, valuations are high ¨C and promoters tend to be more optimistic than realistic. In a sector that has gone through a troubled phase and is making a comeback, promoters have learnt their lessons and are more realistic in their expectations ¨C as also in capital allocation. Pharma is one such sector. And there are more reasons to take a closer look at it.
These large-caps have ¡®strong buy¡¯ & ¡®buy¡¯ recos and upside potential of more than 27%
As the correction continues unabated, a divergence is emerging in what is happening to the Nifty and Sensex and what is happening in the entire large-cap space. There are pockets where a certain amount of relative outperformance is visible. While Reliance Industries might be under pressure, stocks like HDFC Bank ¨C which too has high FPI holding ¨C is able to keep its head above the water even on strongly bearish days. So, probably the broad-brush selling is over. Still, despite the recent correction, valuations are on the higher side. Being selective should thus continue to be key as the markets show the first hint at a possible turnaround. ET Screener powered by Refinitiv¡¯s Stock Report Plus lists down quality stocks with high upside potential over the next 12 months, having an average recommendation rating of ¡°buy¡± or "strong buy". The screener applies different algorithms for all BSE and NSE stocks.
- Go To Page 1
Sensex drops 600 pts, Nifty below 23,400 as slow earnings and FPI outflows weigh on investor mood
Stock Market Today: Indian benchmark equity indices traded lower on Monday, weighed down by concerns over slowing earnings growth and foreign outflows. Additionally, comments from the Federal Reserve Chair signaling a slower pace of interest rate cuts further dampened market sentiment.
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 52%
Whether the market is in the grip of bulls or bears, investors need to be cautious and selective. And when the street is bearish, be careful not to get caught up in short-term narratives and sell at the wrong time. Also, to avoid the urge to average out. While the worst is probably over in the current correction phase, there is a new US administration set to take over and the global markets may still see a readjustment. As an investor, look at sectors and companies in terms of their operating and valuation matrices. If the operating matrix is improving, that¡¯s good. Our list of stocks today depict a strong upward trajectory in their overall average score which is based on five key pillars ¨C earnings, fundamentals, relative valuation, risk, and price momentum. This implies that there has been a significant improvement in their market outlook in the given time frame.
Ignore Nifty, stick to basics of business: 6 stocks from different sectors with an upside potential of up to 42%
When there is a correction and the market breadth is as bad as it has been these past few weeks, it is difficult to stay rational. Yet, the need to stay rational is the highest at this point of time. This is when you need a strong enough reason to buy a stock ¨C and an equally strong reason to sell a part of your portfolio. In the latter case, the fear is that you might end up selling early. For those who think that is not a major issue, just recall the events of 2022 at the start of the Ukraine war. All those who sold in panic then have only earned regrets as returns.
These large-caps have ¡®strong buy¡¯ & ¡®buy¡¯ recos and upside potential of more than 29%
It might be a bit too early to say, but the way things panned out during Monday's trade suggests the worst may be over for the bulls. A typical bottom formation happens when the Nifty and large-caps are relatively stable, but the mid-caps are still under pressure. This is seen as exhaustion of big ticket sales on the street. While it is not a foolproof way of reading the situation, things have worked out this way in the past. In any case, corrections and consolidations are part of every bull market and we will continue to see them at regular levels. And if they are sparked by global events, they may be short time-wise, but in terms of magnitude they could be strong.ET Screener powered by Refinitiv¡¯s Stock Report Plus lists down quality stocks with high upside potential over the next 12 months, having an average recommendation rating of ¡°buy¡± or "strong buy". The screener applies different algorithms for all BSE and NSE stocks.
Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports Plus
Stock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company analyses, the report also collates analysts¡¯ forecasts and trend analysis for each component. An average score in Stock Reports Plus is calculated by undertaking quantitative analysis of five key investment tools ¨C earnings, fundamentals, relative valuation, risk, and price momentum.
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 45%
After a corrective phase sparked by global events, both indices and market breadth have turned positive. In this phase of recovery, when valuations are still high, there are a couple of things investors need to be mindful of. First, check how your target stock fared in terms of Q2 results: Were they better than expected? Second, remain cautious. Keep exposure low for now, and look for stocks with strong fundamentals. The stocks on our list today depict a strong upward trajectory in their overall average score. This implies that there has been a significant improvement in their market outlook in the given time frame.
Trump & Tariffs: Pharma sector might escape the inevitable tariff troubles. 6 pharma stocks, 5 with an upside potential of up to 38%
Exactly eight years ago, in 2016, when a reality TV star became US president, the global markets went into sharp decline on the day of surprise victory. In 2024, the reaction is the opposite ¨C markets are rejoicing at his return. While there is nothing wrong in having a party, better be cognizant of some of the things the next US president brings to the table. One would be tariff wars. While China will be the main focus, there are areas where India will be in the picture. But there is one sector that is unlikely to face any trouble: Pharmaceuticals. There are reasons why it might escape the headwinds, in some cases the change in regime might act as another tailwind.
Dr Reddy's Labs, Mankind Pharma riding on strong growth drivers
Indian pharmaceutical giants, Dr. Reddy's Labs and Mankind Pharma, reported impressive double-digit revenue growth in the September quarter. Dr. Reddy's achieved this milestone despite challenges in Europe and increased expenses, while Mankind Pharma thrived on robust domestic sales and expansion into consumer healthcare. Both companies remain optimistic about future prospects.
Mankind Pharma shares gain over 6% as profit jumps nearly 30% in Q2
Mankind Pharma's shares surged by 6% after reporting a 29% rise in Q2 profits, reaching ?658.88 crore. The company attributed this growth to sales volume recovery, particularly in the chronic segment and domestic sales. Exports also saw a significant 57% increase. Motilal Oswal raised its target price on the stock, citing the company's strong growth prospects.
Gland Pharma shares zoom 12% post Q2 results; Kotak upgrades on limited downside
Gland Pharma Share Price: Gland Pharma shares rose 12% despite a 15.7% YoY profit decline in Q2. Kotak upgraded the stock to 'Reduce' with a revised target price of Rs 1,625, citing improved core business performance.
Sun Pharma shares tumble 4% as US court blocks Leqselvi launch
Sun Pharmaceuticals' shares fell by 3.62% after a US court blocked its launch of Leqselvi until further legal developments or the expiry of a key patent. Sun Pharma plans to appeal the decision. Analysts suggest a potential appeal or settlement to expedite the product launch, with minimal impact if delayed until 2026.
Hot stocks: Brokerage view on M&M, Nykaa and Sun Pharma
JPMorgan reports that Sun Pharma plans to appeal a judgment and may seek a settlement with Incyte to expedite its product launch. In a worst-case scenario, the launch could occur post-expiry in December 2026. The firm assigns an NPV of $546 million for Leqselvi, projecting 20% CAGR growth for the specialty business driven by existing products.
Stocks in news: IRFC, IRCTC, Ujjivan SFB, Bharti Airtel, Sun Pharma
Tata Investment Corporation reported its September quarter net profit at Rs 124 crore, which was flat over the corresponding quarter of the previous financial year.
Stocks in news: Tata Investment, Narayana Hrudalaya, Hero MotoCorp, Bharti Airtel, Alembic Pharma
Equity markets experienced pressure on monthly expiry day, slipping nearly half a percent. Shares of Tata Investment, Narayana Hrudalaya, Hero MotoCorp, Bharti Airtel, and Alembic Pharma will be in focus during Muhurat trading due to quarterly results and key developments. Siemens has scheduled a meeting regarding an arrangement with Siemens Energy.
Torrent Pharma shares fall 3% after 2.9% stake sale via block deal
Torrent Pharma Share Price: Torrent Pharmaceuticals reported a consolidated profit after tax (PAT) of Rs 453 crore in the September quarter, which rose by 17% led by robust sales in the domestic market. The drug firm had reported a PAT of Rs 386 crore in the July-September period of the last fiscal.
Stocks in news: L&T, Tata Power, Dabur, Marico, Torrent Pharma
Shares of Torrent Pharmaceuticals are expected to remain in focus on Wednesday as the company's promoter could sell 2.9% stake worth Rs 3,000 crore via block deal.
Sun Pharma shares tumble 2% despite Q2 profit rising 28% YoY to Rs 3,040 crore. Should you invest?
Sun Pharma Share Price: Sun Pharmaceuticals' shares fell by 2% despite a strong financial performance in the second quarter. The company reported a 28% increase in net profit to Rs 3,040 crore. Analysts have mixed views; Jefferies has a 'Buy' rating, while Goldman Sachs maintains a 'Sell' rating, with concerns about upcoming higher R&D expenses and launch costs.
Volatility is temporary, fundamental tailwinds are permanent: 5 mid-cap pharma stocks with an upside potential of up to 46%
Official Action Indicated (OAI). Not many investors may have heard of this. But they would surely have felt its impact. For, the moment OAI is triggered, the stock price slips sharply. OAI is nothing but the technical term used to describe an action of the US FDA. After inspecting a pharma firm¡¯s plant it may recommend regulatory and/or administrative actions, if needed. There was a time when one would hear of US FDA inspections on Indian pharma plants every second day. The OIA could include a recommendation to stop sourcing drugs from that plant ¨C or some less severe action. This is still happening, but not as often as before. And thereby hangs a tale.
Sun Pharma shares in focus ahead of Q2 results today
Sun Pharma Share Price: Sun Pharma is set to announce its Q2 FY25 results, with revenue growth expected to be driven by domestic business and higher specialty sales in the US. Gross margins may improve sequentially, though EBITDA margins could decline due to increased R&D spending.
Stock Radar: 170% rally in a year! Multibagger pharma stock breaks out from 6-week consolidation; time to buy?
Piramal Pharma has broken out from a 6-week consolidation on weekly charts, now trading above key moving averages and is positioned to rise toward Rs 280 in the next 3-4 weeks. This progression follows a strong uptrend and a breakout from the previous resistance levels.
Load More
